CellCentric Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $219M

  • Investors
  • 23

CellCentric General Information

Description

Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. The company's novel small-molecule inhibitors inhibit the common bromodomain of twin proteins down-regulate the androgen receptor and also deplete the adaptive AR splice variant forms, thereby enabling clients to treat specific cancers and notably relapsed refractory multiple myeloma.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Chesterford Research Park
  • Cambridge CB10 1XL
  • England, United Kingdom
+44 01799
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Chesterford Research Park
  • Cambridge CB10 1XL
  • England, United Kingdom
+44 01799

CellCentric Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CellCentric Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
21. Later Stage VC (Series D) 06-May-2026 $219M Completed Clinical Trials - Phase 1
20. Later Stage VC (Series C) 22-Apr-2025 Completed Clinical Trials - Phase 1
19. Later Stage VC (Series B) 09-Jul-2024 Completed Clinical Trials - Phase 1
18. Later Stage VC (Series A) 30-Jun-2023 Completed Clinical Trials - Phase 1
17. Later Stage VC 22-Oct-2020 Completed Clinical Trials - Phase 1
16. Accelerator/Incubator 01-Jan-2020 Completed Clinical Trials - Phase 1
15. Later Stage VC 15-May-2018 Completed Clinical Trials - Phase 1
14. Later Stage VC 19-Jun-2017 Completed Clinical Trials - Phase 1
13. Grant 08-Nov-2016 $31.1M Completed Clinical Trials - Phase 1
12. Later Stage VC 28-Jul-2016 $5.27M $31.1M Completed Clinical Trials - Phase 1
To view CellCentric’s complete valuation and funding history, request access »

CellCentric Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
D Preferred
C Preferred
B-1 Preferred
B-2 Preferred
A Ordinary
A Ordinary
A Ordinary
A Ordinary
A Ordinary 6,153,846 $0.001350 $0.88 $0.88 1x $0.88 4.62%
A Ordinary 1,482,749 $0.001350 $9.13 $9.13 1x $9.13 1.11%
To view CellCentric’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

CellCentric Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specif
Drug Discovery
Cambridge, United Kingdom
29 As of 2025

Santa Monica, CA
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CellCentric Competitors (47)

One of CellCentric’s 47 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA
MaveriX Oncology Venture Capital-Backed Palo Alto, CA
Adimab Venture Capital-Backed Lebanon, NH
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 47 competitors. Get the full list »

CellCentric Patents

CellCentric Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026171694-A1 Combination therapy for cancer Pending 11-Feb-2025
GB-201806320-D0 Process Inactive 18-Apr-2018
AU-2019256788-A1 Process for preparing modulators of p300 and/or cbp Active 18-Apr-2018
AU-2019256788-B2 Process for preparing modulators of p300 and/or cbp Active 18-Apr-2018
CA-3096441-A1 Process for preparing modulators of p300 and/or cbp Pending 18-Apr-2018 C07D413/14
To view CellCentric’s complete patent history, request access »

CellCentric Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CellCentric Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
American Cancer Society Corporation Minority
Fidelity Management & Research Company Asset Manager Minority
HBM Healthcare Investments Venture Capital Minority
Sofinnova Partners Venture Capital Minority
Venrock Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

CellCentric FAQs

  • When was CellCentric founded?

    CellCentric was founded in 2003.

  • Where is CellCentric headquartered?

    CellCentric is headquartered in Cambridge, United Kingdom.

  • What is the size of CellCentric?

    CellCentric has 29 total employees.

  • What industry is CellCentric in?

    CellCentric’s primary industry is Drug Discovery.

  • Is CellCentric a private or public company?

    CellCentric is a Private company.

  • What is the current valuation of CellCentric?

    The current valuation of CellCentric is .

  • What is CellCentric’s current revenue?

    The current revenue for CellCentric is .

  • How much funding has CellCentric raised over time?

    CellCentric has raised $505M.

  • Who are CellCentric’s investors?

    American Cancer Society, Fidelity Management & Research Company, HBM Healthcare Investments, Sofinnova Partners, and Venrock are 5 of 23 investors who have invested in CellCentric.

  • Who are CellCentric’s competitors?

    Kite Pharma, MaveriX Oncology, Adimab, Carisma Therapeutics, and Adaptimmune Therapeutics are some of the 47 competitors of CellCentric.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process